BridgeBio Pharma Patent-Cliff Exposure & CMS Drug Spending Portfolio
BridgeBio Pharma (Palo Alto, CA): 1 reconciled FDA prescription therapies, $870K 2024 CMS Part D & Medicaid spend, and $18,759 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Palo Alto, CA |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2039-01-01 |
| 2024 CMS Total Public Spend | $870K |
| 2024 Medicare Part D Spend | $870K |
| 2024 Medicaid Spend | $0 |
| California HCAI SB 17 Filings | Specialty launch notice ($18,759 intro WAC) |